Search Within

Erica Simone Dayan

Formats
  1. Journal Article (7)
  2. Meeting Abstract (6)
Groups
  1. Department of Medicine (12)
  2. Genitourinary Oncology Service (12)
  3. Solid Tumor Oncology Division (12)
  4. Biostatistics Service (6)
  5. Epidemiology and Biostatistics (6)
  6. GME, Medicine (3)

More Groups

People
  1. Howard Scher (12)
  2. Michael Morris (6)
  3. Glenn Heller (5)
  4. Daniel Danila (4)
  5. Karen Autio (4)
  6. Niamh Keegan (3)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (3)
  4. 2020 (2)
  5. 2019 (1)
  6. 2018 (2)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Annals of Oncology (1)
  3. European Urology (1)
  4. European Urology Oncology (1)
  5. European Urology Open Science (1)
  6. JCO Oncology Practice (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. Elsevier BV (2)
  3. Elsevier Science, Inc. (2)
  4. Innovative Healthcare Institute (1)
  5. Lippincott Williams & Wilkins (1)
  6. Oxford University Press (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Evaluating immune-related adverse events using PRO-CTCAE in a phase II study of ipilimumab for hormone-sensitive prostate cancer
    Journal Article

    Vargas P. de Almeida, D.; Anderson, J. M.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Cohn, E. D.; Baser, R. E.; Scher, H. I.; Autio, K. A.
    Journal of Immunotherapy and Precision Oncology (2023)

    Fulltext@MSK | Save
  • Chromosomal instability (CIN) in circulating tumor cells (CTC) predicts for taxane sensitivity in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Arfe, A.; Barnett, E.; Cohn, E. D.; Zhao, J.; Carbone, E.; Zanone, M.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Spine pain and metastatic prostate cancer: Defining the contribution of nonmalignant etiologies
    Journal Article

    Ruppert, L. M.; Cohn, E. D.; Keegan, N. M.; Bacharach, A.; Woo, S.; Gillis, T.; Scher, H. I.
    JCO Oncology Practice (2022)

    Fulltext@MSK | Save
  • Randomized phase 2 trial of abiraterone acetate plus prednisone, degarelix, or the combination in men with biochemically recurrent prostate cancer after radical prostatectomy
    Journal Article

    Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Shevrin, D. H.; Stein, M. N.; Vaishampayan, U. N.; Morris, M. J.; Slovin, S. F.; Heath, E. I.; Tagawa, S. T.; more...
    European Urology Open Science (2021)

    Fulltext@MSK | Save
  • Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Schonhoft, J.; Barnett, E.; Cohn, E. D.; Zhao, J. L.; Carbone, E. A.; Zanone, M. R.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase 3 randomized controlled trial of androgen deprivation therapy with or without docetaxel in high-risk biochemically recurrent prostate cancer after surgery (TAX3503)
    Journal Article

    Morris, M. J.; Mota, J. M.; Lacuna, K.; Hilden, P.; Gleave, M.; Carducci, M. A.; Saad, F.; Cohn, E. D.; Filipenko, J.; Heller, G.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Regional patterns of fluid and fat accumulation in patients with lower extremity lymphedema using magnetic resonance angiography
    Journal Article

    Dayan, J. H.; Wiser, I.; Verma, R.; Shen, J.; Talati, N.; Goldman, D.; Mehrara, B. J.; Smith, M. L.; Dayan, E.; Coriddi, M.; more...
    Plastic and Reconstructive Surgery (2020)

    Fulltext@MSK | Save
  • Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: A randomized phase 3 trial with a primary pain endpoint
    Journal Article

    Basch, E. M.; Scholz, M.; de Bono, J. S.; Vogelzang, N.; de Souza, P.; Marx, G.; Vaishampayan, U.; George, S.; Schwarz, J. K.; Antonarakis, E. S.; more...
    European Urology (2019)

    Fulltext@MSK | Save
  • An integrated medical oncology-psychiatry practice model improves overall patient functionality of prostate cancer patients by identifying, quantifying and treating the pre-existing non-cancer co-morbidities
    Meeting Abstract

    Ruppert, L. M.; Dayan, E. S.; Bacharach, A.; Scher, H. I.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save